Job title: CEO
Matthias holds a Master’s degree in Biotechnology and a Ph.D. in Biochemistry from BOKU University Vienna. Before becoming co-founder and CEO of TAmiRNA in 2013, Matthias led several genomic research projects in academia, including fellowships at the University of Minnesota and University Bielefeld to decipher the non-coding RNA transcriptome in mammalian cell lines. He has several years of experience in in-vitro diagnostics development with a focus on microRNA biomarkers in liquid biopsies. At TAmiRNA, Dr. Hackl and his team are currently developing applications of microRNA biomarkers in the area of osteoporosis, liver and cardiovascular disease, toxicology and aging/senescence. Dr. Hackl has published 60 peer-reviewed papers with an h-index of 24, and has received several national and international scientific and entrepreneurship awards.
senomiRs® – circulating microRNA biomarkers for diagnosis of senescence burden and treatment response 12:05 pm
day: Day One